Filipe A Moura, PhD

2026

• Efficacy and Safety of Olezarsen in Patients with Versus without Baseline Fibrate Use

  Wang A, Alexander V, Prohaska T, Ran X, Goodrich E, Murphy S, Zimerman A, Moura F, Kang Y, Nordestgaard B, Stroes E, Gaudet D, Badimon L, Duarte J, Ferreira J, Vinereanu D, Pella D, Dzupina A, Tsimikas S, Giugliano R, Sabatine M, Marston N, Bergmark B. Efficacy and Safety of Olezarsen in Patients with Versus without Baseline Fibrate Use. Journal Of Clinical Lipidology 2026 PMID: 42674889, DOI: 10.1016/j.jacl.2026.08.001.

  Peer-Reviewed Original Research

  Citations

  Altmetric

• Don’t Sleep on the Other Beds: Atherosclerosis Across Heart, Brain, and Limbs

  Zimerman A, Moura F. Don’t Sleep on the Other Beds: Atherosclerosis Across Heart, Brain, and Limbs. American Journal Of Preventive Cardiology 2026, 101728. DOI: 10.1016/j.ajpc.2026.101728.

  Commentaries, Editorials and Letters

• Beyond the apnea-hypopnea index: Precision cardiovascular risk stratification in obstructive sleep apnea

  Gaffey A, Moura F. Beyond the apnea-hypopnea index: Precision cardiovascular risk stratification in obstructive sleep apnea. American Journal Of Preventive Cardiology 2026, 28: 101690. PMID: 42597707, PMCID: PMC13469287, DOI: 10.1016/j.ajpc.2026.101690.

  Commentaries, Editorials and Letters

  Altmetric

• Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis

  Oscarsson J, Huhn M, Jiang Y, Gause‐Nilsson I, Wiviott S, Moura F, Wilding J, Cernea S, Van Gaal L, Cahn A, Bhatt D, Johansson P, Sjöström C. Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis. Diabetes Obesity And Metabolism 2026, 28: 6142-6150. PMID: 42046405, PMCID: PMC13243968, DOI: 10.1111/dom.70820.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  MeSH Keywords

• Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study

  Marston N, Bergmark B, Prohaska T, Moura F, Zimerman A, Alexander V, Kang Y, Weinland J, Ran X, Murphy S, Zhang S, Li D, Banach M, Stroes E, Kiss R, Gaudet D, Vrablik M, Goudev A, Bax J, Budoff M, Foldyna B, Lu M, Tsimikas S, Giugliano R, Sabatine M. Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study. Circulation 2026, 153: 1539-1548. PMID: 41910513, DOI: 10.1161/circulationaha.126.080012.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  MeSH Keywords

• DOTA-based perfusion imaging in hybrid positron emission tomography/magnetic resonance: Promise, limits, and the importance of tracer kinetics

  Moura F, Sinusas A. DOTA-based perfusion imaging in hybrid positron emission tomography/magnetic resonance: Promise, limits, and the importance of tracer kinetics. Journal Of Nuclear Cardiology 2026, 59: 102703. PMID: 41905549, DOI: 10.1016/j.nuclcard.2026.102703.

  Commentaries, Editorials and Letters

• Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial

  Kimura-Medorima S, Oliveira D, Breder I, Wolf V, Soares A, Barreto J, Munhoz D, Cunha J, Bonilha I, de Carvalho L, Coelho-Filho O, Matos-Souza J, Moura F, Nadruz W, Quinaglia T, Sposito A. Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial. Cardiovascular Diabetology 2026, 25: 140. PMID: 41888924, PMCID: PMC13141266, DOI: 10.1186/s12933-026-03142-y.

  Peer-Reviewed Original Research

  MeSH Keywords

• A Multicenter Randomized Clinical Trial of Dapagliflozin in Patients Receiving Chronic Dialysis (The DARE-ESKD-2 Trial)

  Barreto J, Martins M, Silva C, Jesus D, Baldini M, Oliveira A, da Silva Quadros K, Carbonara C, Silva G, Campos-Staffico A, Zimerman A, Moura F, Coelho-Filho O, Matos-Souza J, Assato B, Bonilha I, Gomes E, Kimura-Medorima S, Nadruz W, Oliveira R, Sposito A. A Multicenter Randomized Clinical Trial of Dapagliflozin in Patients Receiving Chronic Dialysis (The DARE-ESKD-2 Trial). Kidney International Reports 2026, 11: 106355. PMID: 41970273, PMCID: PMC13069122, DOI: 10.1016/j.ekir.2026.106355.

  Peer-Reviewed Original Research

  Citations

  Altmetric

• Low-Dose CT as a Diagnostic Clue: Unmasking Anemia as a Cause of Reduced Myocardial Flow Reserve on PET/CT

  Ambrosini A, Vashist A, Sinusas A, Moura F. Low-Dose CT as a Diagnostic Clue: Unmasking Anemia as a Cause of Reduced Myocardial Flow Reserve on PET/CT. Journal Of Nuclear Cardiology 2026, 102646. PMID: 41580018, DOI: 10.1016/j.nuclcard.2026.102646.

  Peer-Reviewed Original Research

  This case investigates how low-dose CT imaging can identify anemia as a cause of reduced myocardial flow reserve, aiding accurate diagnosis and preventing misclassification of coronary conditions.

  Full Summary

• A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes

  Abel E, Ahima R, Anderson E, Berg D, Berger J, Das S, Feinberg M, Fisher E, Garshick M, Giannarelli C, Goldberg I, Hamburg N, Kim S, Moura F, Ndumele C, Newman J, Sabatine M, Selvin E, Shah R. A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes. Circulation Research 2026, 138: e325798. PMID: 41538415, PMCID: PMC13533177, DOI: 10.1161/circresaha.125.325798.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  Citations

  Altmetric

  MeSH Keywords